tesetaxel + capecitabine + cisplatin

Tesetaxel + capecitabine + cisplatin is a combination chemotherapy regimen under investigation for the treatment of advanced gastric cancer and potentially other solid tumors. Tesetaxel is an orally administered taxane that inhibits microtubule depolymerization, leading to cell cycle arrest and apoptosis. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) that interferes with DNA synthesis by inhibiting thymidylate synthase after conversion to 5-FU in tumor tissue. Cisplatin is a platinum-based alkylating agent that crosslinks DNA strands, preventing replication and transcription, ultimately causing cell death. The combination leverages non-overlapping mechanisms of action to enhance antitumor efficacy[2][3][4][7].

Other names

tesetaxelcapecitabinecisplatinCX